Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05775159 · ClinicalTrials.gov registry record · Phase 2

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

A Phase 2 study of Hepatocellular Carcinoma and Biliary Tract Cancer, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 2
Development phase
294
Enrollment target
20
Study locations

NCT05775159 is a Phase 2 study of Hepatocellular Carcinoma and Biliary Tract Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 294 participants, above the 255-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (15% higher). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05775159, a Phase 2 study of Hepatocellular Carcinoma and Biliary Tract Cancer, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 2
Development phase
294 participants
Enrollment target
20
Study locations

Study Summary

GEMINI-Hepatobiliary study will assess the efficacy, safety and tolerability of novel immunomodulators alone and in combination with other anticancer drugs in participants with specified advanced solid tumors.

Conditions Studied

Hepatocellular Carcinoma Biliary Tract Cancer

Interventions

  • DRUG Bevacizumab
  • DRUG Gemcitabine
  • DRUG Rilvegostomig
  • DRUG Lenvatinib
  • DRUG Volrustomig

Study Locations (20)

Other

  • Research Site - Beijing
  • Research Site - Beijing
  • Research Site - Beijing
  • Research Site - Chengdu
  • Research Site - Chengdu
  • Research Site - Chongqing
  • Research Site - Fuzhou
  • Research Site - Guangzhou
  • Research Site - Guangzhou
  • Research Site - Harbin

California

  • Research Site - Costa Mesa
  • Research Site - Los Angeles
  • Research Site - Orange

Alabama

  • Research Site - Birmingham

Florida

  • Research Site - Miami Beach

Indiana

  • Research Site - Dyer

Kansas

  • Research Site - Kansas City

New York

  • Research Site - New York

Texas

  • Research Site - Dallas

Trial Details

FieldValue
Enrollment Target 294 participants
Start Date 2023-04-24
Est. Completion 2027-10-28
Phase Phase 2

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05775159

The ClinicalTrials.gov registry entry for NCT05775159 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 294 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 255-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (15% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Bevacizumab is the first listed.

NCT05775159 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, California, Alabama.

Frequently Asked Questions

What is clinical trial NCT05775159 about?

NCT05775159 is a clinical study titled "Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer". GEMINI-Hepatobiliary study will assess the efficacy, safety and tolerability of novel immunomodulators alone and in combination with other anticancer drugs in participants with specified advanced solid tumors.

What is the current status of trial NCT05775159?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 294 participants. The study started on 2023-04-24. Estimated completion is 2027-10-28.

What conditions does trial NCT05775159 study?

This clinical trial studies the following conditions: Hepatocellular Carcinoma, Biliary Tract Cancer.

What interventions are being tested in trial NCT05775159?

The interventions under investigation include: Bevacizumab (DRUG), Gemcitabine (DRUG), Rilvegostomig (DRUG), Lenvatinib (DRUG), Volrustomig (DRUG).

Who is sponsoring clinical trial NCT05775159?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05775159 being conducted?

This trial has 20 study locations across Alabama, California, Florida, Indiana, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hepatocellular Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hepatocellular Carcinoma

All registered trials for this condition

Biliary Tract Cancer

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.